Myostatin Inhibitor (Myostatin Inhibitor Peptides (Anti-GDF-8))
Synthetic peptides blocking myostatin signaling, the primary negative regulator of muscle mass. Multiple approaches including propeptide mimics and receptor-blocking peptides.
How it works
Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth.
Key facts
- Molecular weight: 2,000-15,000 Da (varies)
- Half-life: 4-48 hours (design-dependent)
- Bioavailability: Variable (SubQ)
- Storage: Lyophilized: -20°C.
Dosing overview
- Typical dose: 50-500 mcg
- Frequency: 3-7x per week
- Duration: 4-12 weeks
- Route: Subcutaneous
Reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Possible side effects
- Limited safety data
- Tendon stress potential
- Cardiac hypertrophy risk (theoretical)
Research
- Myostatin propeptide peptides as growth enhancers (2022): Increased hindlimb muscle mass by 25% with improved grip strength and endurance.
- Clinical landscape of myostatin inhibition (2023): Anti-myostatin approaches show 3-5% lean mass gains; combination with exercise adds 8% benefit.
Compare Myostatin Inhibitor
Community discussions about Myostatin Inhibitor
- Tendon soreness after low‑dose myostatin inhibitor – anyone else see this? - 4 comments
- Thoughts on the Performance Stack – Do the claims hold water? - 10 comments
- First time trying a myostatin inhibitor peptide – how do I mix and inject it safely? - 4 comments
- ACE-031 development halted over vascular side effects, worth revisiting? - 5 comments
- Ask the community about Myostatin Inhibitor
Research and educational reference only. Not medical advice.